Specification
| Target | TROP2 |
| Clone | Sacituzumab |
| Isotype | Human IgG1(E356D/M358L)-kappa |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | Anti-HEL Human IgG1(E356D/M358L)-Kappa Isotype control |
| Recommended Dilution Buffer | PBS, pH 7.103 |
| Formulation | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents.1 Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment.7 One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38. Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated approval for the treatment of mTNBC patients who have undergone two or more prior therapies. As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.1 In November 2021, sacituzumab govitecan was also approved by the European Commission. |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |